Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | MVD | P53602 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 3/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28480515 | 0.98 | BTN3A1 (0.48) | BTN3A1PPARDMVDTSHRFDPS | |
| SCHEMBL609969 | 0.95 | BTN3A1 (0.54) | BTN3A1PPARDMVDTSHRFDPS | |
| SCHEMBL27571820 | 0.93 | BTN3A1 (0.52) | BTN3A1PPARDMVDTSHRFDPS | |
| Phosphine SCHEMBL28287398 | 0.93 | BTN3A1 (0.52) | BTN3A1PPARDMVDTSHRFDPS | |
| SCHEMBL21831402 | 0.93 | BTN3A1 (0.52) | BTN3A1PPARDMVDTSHRFDPS | |
| SCHEMBL8414470 | 0.93 | BTN3A1 (0.52) | BTN3A1PPARDMVDTSHRFDPS | |
| SCHEMBL29046842 | 0.93 | BTN3A1 (0.52) | BTN3A1PPARDMVDTSHRFDPS | |
| SCHEMBL29221154 | 0.93 | BTN3A1 (0.52) | BTN3A1PPARDMVDTSHRFDPS | |
| SCHEMBL627986 | 0.90 | PPARD (0.54) | BTN3A1PPARDMVDTSHRTDP1 | |
| Ammonia Solution, Strong SCHEMBL628386 | 0.87 | PPARD (0.52) | BTN3A1PPARDMVDTSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117653785-A | Bioactive coating on surface of skull repairing titanium mesh and preparation method thereof | 中国科学院宁波材料技术与工程研究所 | 2024-03-08 | — | — | CN | claimed |
| CN-104225676-B | Containing the application in osteochondral defect is repaired of the lithium nature material bioactive bracket | 浙江大学 | 2016-08-24 | — | — | CN | claimed |
| CN-104415668-A | Making method of organic-inorganic hybrid separating membrane | DALIAN CHEMICAL PHYSICS INST | 2015-03-18 | — | — | CN | claimed |
| CN-104225676-A | Application of lithium-containing natural material bioactive scaffold in osteochondral defect repair | UNIV ZHEJIANG | 2014-12-24 | — | — | CN | claimed |
| CN-101843919-A | Method for preparing hydroxyapatite/composite hole bioactive glass | UNIV HARBIN NORMAL | 2010-09-29 | — | — | CN | claimed |
| US-5620676-A | ADENOSINE TRIPHOSPHATE DERIVATIVES; TREATMENT OF SEPTIC SHOCK OR BRAIN SEIZURES, LEARNING ENHANCEMENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-04-15 | — | — | US | claimed |
| CN-118491320-A | Composite membrane with sandwich structure and preparation method and application thereof | 河北科技大学 | 2024-08-16 | — | — | CN | disclosed |
| CN-117577945-B | Electrolyte and secondary battery | 宁德时代新能源科技股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117653785-A | Bioactive coating on surface of skull repairing titanium mesh and preparation method thereof | 中国科学院宁波材料技术与工程研究所 | 2024-03-08 | — | — | CN | disclosed |
| CN-117577945-A | Electrolyte and secondary battery | 宁德时代新能源科技股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023185158-A1 | PROCESSING APPARATUS FOR VACUUM HEAT-INSULATING PLATE, AEROGEL-MODIFIED POLYURETHANE FOAM THERMAL INSULATION PLATE, AND PREPARATION METHOD THEREFOR | 重庆再升科技股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| CN-115667535-A | WPRE mutant constructs, compositions, and methods thereof | 伊玛提克斯美国公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115461425-A | Viscosity modifier and curable composition | 楠本化成株式会社 | 2022-12-09 | — | — | CN | disclosed |
| WO-2010028676-A1 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT | MONDOBIOTECH LABORATORIES AG (LI) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009046856-A2 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT | MONDOBIOTECH LABORATORIES AG (LI) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009040086-A2 | USE OF SALUSIN-ALPHA AS A THERAPEUTIC AGENT | MONDOBIOTECH LABORATORIES AG (LI) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009033788-A2 | USE OF A JCK-301, OPTIONALLY IN COMBINATION WITH BIG ENDOTHELIN, AS A THERAPEUTIC AGENT. | MONDOBIOTECH LABORATORIES AG (LI) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009033790-A2 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT | MONDOBIOTECH LABORATORIES AG (LI) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009033792-A2 | GAMMA 1 MSH ALONE OR IN COMBINATION WITH PENTAGASTRIN AS A THERAPEUTIC AGENT | MONDOBIOTECH LABORATORIES AG (LI) | 2009-03-19 | — | — | WO | disclosed |
| US-5620676-A | ADENOSINE TRIPHOSPHATE DERIVATIVES; TREATMENT OF SEPTIC SHOCK OR BRAIN SEIZURES, LEARNING ENHANCEMENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-04-15 | — | — | US | disclosed |